In a report released today, Rami Katkhuda from LifeSci Capital maintained a Buy rating on Disc Medicine (IRON – Research Report), with a price target of $85.00.
Protect Your Portfolio Against Market Uncertainty
- Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter.
- Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox.
Rami Katkhuda has given his Buy rating due to a combination of factors that highlight Disc Medicine’s promising financial and clinical position. The company reported strong financial health with $694.7 million in cash and marketable securities, which is projected to support operations until 2028. This financial stability provides a solid foundation for ongoing and future clinical developments.
Additionally, Disc Medicine’s pipeline shows significant potential, particularly with the ongoing APOLLO study for bitopertin. The study aims to evaluate the safety and efficacy of bitopertin in EPP patients, with promising preliminary results from earlier trials showing substantial reductions in PPIX levels and improvements in sunlight tolerance. The company is also preparing for an NDA submission for bitopertin under the accelerated approval pathway, further indicating the potential for regulatory success. These factors collectively contribute to the positive outlook and Buy rating for Disc Medicine’s stock.
Based on the recent corporate insider activity of 55 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of IRON in relation to earlier this year.